News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Provides Business Update
SAN DIEGO , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , said, “We have been receiving a considerable amount of inquiries from investors,
Adamis Pharmaceuticals Provides Business Update
SAN DIEGO , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , said, “We have been receiving a considerable amount of inquiries from investors,
Toggle Summary Adamis Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update
SAN DIEGO , Aug. 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2018 and a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Adamis Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update
SAN DIEGO , Aug. 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2018 and a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Toggle Summary Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the closing of
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the closing of
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the pricing of
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the pricing of
Toggle Summary Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today that it
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today that it
Toggle Summary Adamis Pharmaceuticals Adds Sublingual Erectile Dysfunction Product Candidate to its Pipeline
SAN DIEGO , July 23, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil.  Adamis intends to submit an investigational new drug (IND)
Adamis Pharmaceuticals Adds Sublingual Erectile Dysfunction Product Candidate to its Pipeline
SAN DIEGO , July 23, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil.  Adamis intends to submit an investigational new drug (IND)
Toggle Summary Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for Symjepi
SAN DIEGO , July 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc. (“Sandoz”), a division of the Novartis Group , to commercialize Adamis’
Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for Symjepi
SAN DIEGO , July 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc. (“Sandoz”), a division of the Novartis Group , to commercialize Adamis’
Toggle Summary Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
SAN DIEGO , May 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced financial results and a business update for the first quarter ended March 31, 2018 . Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , said, “We have
Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
SAN DIEGO , May 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced financial results and a business update for the first quarter ended March 31, 2018 . Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , said, “We have
Toggle Summary Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update
SAN DIEGO , March 15, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided investors with an update concerning certain accomplishments for 2017 and accomplishments and goals for 2018. 2017 Highlights As reflected in the company’s annual report on Form 10-K for
Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update
SAN DIEGO , March 15, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided investors with an update concerning certain accomplishments for 2017 and accomplishments and goals for 2018. 2017 Highlights As reflected in the company’s annual report on Form 10-K for
Toggle Summary Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and Immunology
SAN DIEGO , March 08, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that a study titled “Human Factors Study in Untrained Adolescents Comparing Its Epinephrine Prefilled Syringe (Symjepi™) with EpiPen® Auto-Injector” was recently published in
Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and Immunology
SAN DIEGO , March 08, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that a study titled “Human Factors Study in Untrained Adolescents Comparing Its Epinephrine Prefilled Syringe (Symjepi™) with EpiPen® Auto-Injector” was recently published in